Compare Dow Inc (DOW) vs Moderna, Inc. (MRNA) Price & Performance

DOW trades at $30.64, up 0.2% with a bullish technical signal and recent earnings beats. The company shows declining revenue trends from $56.9B in 2022 to $40.0B in 2025, with negative net income margins. Analyst consensus is mixed with 33% buy ratings and a $35.11 price target, representing 15% upside. Recent dividend payment of $0.35 provides income support amid challenging fundamentals.

While technical indicators suggest near-term strength, fundamental challenges persist with negative profitability and declining cash flow. The stock offers potential upside to analyst targets but faces execution risks in a competitive chemical sector. Dividend yield provides some cushion, but investors need sustained operational improvement for meaningful long-term returns.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.